Pages

Thursday, 28 February 2019

Celgene Stock Tumbles As Bristol's Top Shareholder Opposes Merger - Investor's Business Daily

Celgene Stock Tumbles As Bristol's Top Shareholder Opposes Merger  Investor's Business Daily

Celgene stock plunged late Wednesday after Bristol-Myers Squibb's top shareholder said it opposes the $74 billion biopharma merger. Bristol stock rose.



Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)